Home › Companies › ACADIA PHARMACEUTICALS INC. › 2024-2025

ACADIA PHARMACEUTICALS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ACADIA PHARMACEUTICALS INC.’s Form 8-K, filed 2025-05-29 (Item 5.07 on EDGAR). Page generated 04 October 2026.

7Reported items
344Asset managers
1,969Fund votes
2025-05-29Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ACADIA PHARMACEUTICALS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ACADIA PHARMACEUTICALS INC.

These tallies are ACADIA PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-29 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ACADIA PHARMACEUTICALS INC. — official shareholder meeting results, meeting held 2025-05-29
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Catherine Owen Adams	142,149,434	--	--	2,923,385	10,343,307	Majority: yes
Elect Director: Laura A. Brege	129,105,717	--	--	15,967,102	10,343,307	Majority: yes
Elect Director: Elizabeth A. Garofalo, M.D.	140,048,500	--	--	5,024,319	10,343,307	Majority: yes
In addition to the election of three Class III directors, the following matters were submitted to a vote of the stockholders at the 2025 Annual Meeting:	142,156,754	2,807,251	108,814	--	10,343,307	Majority: yes

Source: ACADIA PHARMACEUTICALS INC., Form 8-K, filed with the SEC on 2025-05-29 — read the filing on EDGAR.

How asset managers voted at the ACADIA PHARMACEUTICALS INC. 2024-2025 meeting

Each item below shows how the 344 asset managers that disclosed a ACADIA PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of ACADIA PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.

SECTION 14A SAY-ON-PAY VOTES

Combines 10 wordings of this item as funds reported it.

99.2% fund support · no official result

FOR 99.2%

The 330 asset managers below cast 99.2% of the shares they voted on this item FOR (147,599,744 for, 1,080,087 against).

FOR: 147,599,744 (99.3%)AGAINST: 1,080,087 (0.7%)ABSTAIN: 16,667 (0.0%)NOT VOTED: 6,522 (0.0%)

Largest asset managers voting on “To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in ” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
BAKER BROS. ADVISORS LP	43,083,688	0	For
Vanguard	15,640,434	17,185	For
BlackRock	14,407,710	0	For
State Street	10,756,855	13,237	For
RTW INVESTMENTS, LP	6,824,479	0	For
Point72	5,430,913	0	For
American Century	3,650,935	0	For
Fidelity	3,213,472	0	For
GEODE CAPITAL MANAGEMENT, LLC	2,974,976	0	For
First Trust	2,518,938	0	For
Charles Schwab	2,194,417	0	For
DE Shaw	1,848,380	0	For
John Hancock	1,696,041	0	For
WEATHERBIE CAPITAL, LLC	1,692,467	0	For
Northern Trust	1,195,323	0	For
Two Sigma	1,185,683	0	For
Dimensional	1,104,916	0	For
Nuveen	1,092,489	0	For
TIAA	1,080,741	0	For
T. Rowe Price	1,022,314	0	For
Goldman Sachs	963,004	0	For
ROCKEFELLER FINANCIAL LLC	876,348	0	For
MUTUAL FUND SERIES TRUST	852,845	0	For
JACOBS LEVY EQUITY MANAGEMENT, INC	839,770	0	For
ALGER FUNDS	796,648	0	For

Showing the 25 largest of 330 asset managers. See all 330 in the interactive database.

2. To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Catherine Owen Adams

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 4 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 142,149,434WITHHELD: 2,923,385

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Catherine Owen Adams”): 142,149,434 for, 2,923,385 withheld, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 167,116,045 outstanding shares: 85% for, 2% withheld (87% of the company cast a for/withheld vote).

The 95 asset managers below cast 100% of the shares they voted on this item FOR (48,757,107 for, 0 against).

FOR 99%

FOR: 48,757,107 (98.8%)ABSTAIN: 599,508 (1.2%)

Largest asset managers voting on “To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Cat” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	15,248,011	2	For
BlackRock	10,085,110	0	For
State Street	4,190,066	0	For
Fidelity	3,051,362	0	For
First Trust	2,492,130	0	For
American Century	1,747,917	0	For
Charles Schwab	1,083,011	0	For
TIAA	1,080,741	0	For
John Hancock	916,097	0	For
Dimensional	879,829	0	For
MUTUAL FUND SERIES TRUST	852,845	0	For
ALGER FUNDS	796,648	0	For
Columbia Threadneedle	613,824	0	For
T. Rowe Price	415,304	0	For
Janus Detroit Street Trust	364,367	0	For
Equitable	333,495	0	For
Goldman Sachs	317,126	0	For
World Funds Trust	300,000	0	For
Erste Asset Management GmbH	0	242,300	Abstain
Principal	119,845	117,890	For
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	For
Jackson National	231,693	0	For
QUANTITATIVE MASTER SERIES LLC	206,561	0	For
Exchange Place Advisors Trust	188,100	0	For
Prudential/PGIM	179,147	0	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

3. To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Elizabeth A. Garofalo, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 140,048,500WITHHELD: 5,024,319

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Elizabeth A. Garofalo, M.D.”): 140,048,500 for, 5,024,319 withheld, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 167,116,045 outstanding shares: 84% for, 3% withheld (87% of the company cast a for/withheld vote).

The 95 asset managers below cast 100% of the shares they voted on this item FOR (47,675,456 for, 0 against).

FOR 97%

FOR: 47,675,456 (96.6%)ABSTAIN: 1,681,159 (3.4%)

Largest asset managers voting on “To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Eli” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	15,248,008	5	For
BlackRock	10,085,110	0	For
State Street	4,190,066	0	For
Fidelity	3,051,362	0	For
First Trust	2,492,130	0	For
American Century	1,747,917	0	For
Charles Schwab	1,083,011	0	For
TIAA	1,080,741	0	For
John Hancock	916,097	0	For
Dimensional	879,829	0	For
MUTUAL FUND SERIES TRUST	852,845	0	For
ALGER FUNDS	796,648	0	For
Columbia Threadneedle	613,824	0	For
T. Rowe Price	0	415,304	Abstain
Janus Detroit Street Trust	364,367	0	For
Equitable	191,115	142,380	For
Goldman Sachs	317,126	0	For
World Funds Trust	300,000	0	For
Erste Asset Management GmbH	0	242,300	Abstain
Principal	119,845	117,890	For
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	For
Jackson National	14,382	217,311	Abstain
QUANTITATIVE MASTER SERIES LLC	206,561	0	For
Exchange Place Advisors Trust	188,100	0	For
Prudential/PGIM	179,147	0	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

4. To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Laura A. Brege

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 5 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 129,105,717WITHHELD: 15,967,102

ACADIA PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Laura A. Brege”): 129,105,717 for, 15,967,102 withheld, per its Form 8-K filed 2025-05-29 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 167,116,045 outstanding shares: 77% for, 10% withheld (87% of the company cast a for/withheld vote).

The 95 asset managers below cast 100% of the shares they voted on this item FOR (41,443,245 for, 0 against).

FOR 84%ABSTAIN 16%

FOR: 41,443,245 (84.0%)ABSTAIN: 7,913,370 (16.0%)

Largest asset managers voting on “To elect three Class III directors to hold office until the Company's 2028 Annual Meeting of Stockholders: Lau” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	15,247,996	17	For
BlackRock	10,085,110	0	For
State Street	16,768	4,173,298	Abstain
Fidelity	3,051,362	0	For
First Trust	2,492,130	0	For
American Century	1,747,917	0	For
Charles Schwab	1,083,011	0	For
TIAA	0	1,080,741	Abstain
John Hancock	821,803	94,294	For
Dimensional	0	879,829	Abstain
MUTUAL FUND SERIES TRUST	852,845	0	For
ALGER FUNDS	796,648	0	For
Columbia Threadneedle	613,824	0	For
T. Rowe Price	0	415,304	Abstain
Janus Detroit Street Trust	364,367	0	For
Equitable	191,115	142,380	For
Goldman Sachs	317,126	0	For
World Funds Trust	300,000	0	For
Erste Asset Management GmbH	242,300	0	For
Principal	119,592	118,143	For
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	For
Jackson National	0	231,693	Abstain
QUANTITATIVE MASTER SERIES LLC	206,561	0	For
Exchange Place Advisors Trust	188,100	0	For
Prudential/PGIM	165,950	13,197	For

Showing the 25 largest of 95 asset managers. See all 95 in the interactive database.

5. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.

AUDIT-RELATED

99.9% fund support · no official result

FOR 99.9%

The 91 asset managers below cast 99.9% of the shares they voted on this item FOR (48,994,846 for, 2,442 against).

FOR: 48,994,846 (100.0%)AGAINST: 2,442 (0.0%)ABSTAIN: 16,667 (0.0%)

Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Vote
Vanguard	15,248,012	1	For
BlackRock	10,085,110	0	For
State Street	4,189,808	258	For
Fidelity	3,051,362	0	For
First Trust	2,492,130	0	For
American Century	1,747,917	0	For
Charles Schwab	1,083,011	0	For
TIAA	1,080,741	0	For
John Hancock	916,097	0	For
Dimensional	879,829	0	For
MUTUAL FUND SERIES TRUST	852,845	0	For
ALGER FUNDS	796,648	0	For
Columbia Threadneedle	613,824	0	For
T. Rowe Price	415,304	0	For
Janus Detroit Street Trust	364,367	0	For
Equitable	333,495	0	For
Goldman Sachs	317,126	0	For
World Funds Trust	300,000	0	For
Principal	237,735	0	For
LIBERTY ALL STAR GROWTH FUND INC.	232,695	0	For
Jackson National	231,693	0	For
QUANTITATIVE MASTER SERIES LLC	206,561	0	For
Exchange Place Advisors Trust	188,100	0	For
Prudential/PGIM	179,147	0	For
Lincoln Financial	173,769	0	For

Showing the 25 largest of 91 asset managers. See all 91 in the interactive database.

6. Advisory Vote to Ratify Named Executive Officers' Compensation

SECTION 14A SAY-ON-PAY VOTES

68% fund support · no official result

FOR 53.8%AGAINST 25%ABSTAIN 21%

The 9 asset managers below cast 68% of the shares they voted on this item FOR (612,749 for, 283,044 against).

FOR: 612,749 (53.8%)AGAINST: 283,044 (24.9%)ABSTAIN: 242,300 (21.3%)

Largest asset managers voting on “Advisory Vote to Ratify Named Executive Officers' Compensation” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
JPMorgan	293,289	0	0	For
NORDEA INVESTMENT MANAGEMENT AB	0	283,044	0	Against
Erste Asset Management GmbH	0	0	242,300	Abstain
ALGERT GLOBAL LLC	214,620	0	0	For
Empower	92,413	0	0	For
Vinva Investment Management Ltd	4,480	0	0	For
CLEARWATER INVESTMENT TRUST	4,216	0	0	For
Virtus	3,689	0	0	For
UNIFIED SERIES TRUST	42	0	0	For

7. Ratify Ernst & Young LLP as Auditors

AUDIT-RELATED

100% fund support · no official result

FOR 100%

The 4 asset managers below cast 100% of the shares they voted on this item FOR (338,971 for, 0 against).

FOR: 338,971 (100.0%)

Largest asset managers voting on “Ratify Ernst & Young LLP as Auditors” at ACADIA PHARMACEUTICALS INC., 2024-2025
Asset manager	For	Vote
Erste Asset Management GmbH	242,300	For
Empower	92,413	For
CLEARWATER INVESTMENT TRUST	4,216	For
UNIFIED SERIES TRUST	42	For

Largest ACADIA PHARMACEUTICALS INC. shareholders voting in 2024-2025

Ranked by the number of ACADIA PHARMACEUTICALS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 167,116,045 shares outstanding at the time of that meeting.

Top ACADIA PHARMACEUTICALS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	BAKER BROS. ADVISORS LP	25.78%
2	Vanguard	9.37%
3	BlackRock	8.62%
4	State Street	6.44%
5	RTW INVESTMENTS, LP	4.08%
6	Point72	3.25%
7	American Century	2.18%
8	Fidelity	1.92%
9	GEODE CAPITAL MANAGEMENT, LLC	1.78%
10	First Trust	1.51%

Reported ACADIA PHARMACEUTICALS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

ACADIA PHARMACEUTICALS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Baker Bros. Advisors LP	25.93%	DEF14A
Julian C. Baker	25.93%	DEF14A
Stephen R. Biggar	25.87%	DEF14A
BlackRock	12.79%	13F
Vanguard Group	9.10%	13F
RTW Investments, LP	4.28%	13G
State Street	4.18%	13F
Morgan Stanley	2.80%	13F
Point72	2.78%	13F
Geode Capital	1.77%	13F

Percentages above are of 167,116,045 shares outstanding, as reported by ACADIA PHARMACEUTICALS INC. on its Form 10-Q dated 2025-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ACADIA PHARMACEUTICALS INC.’s 10-Q dated 2025-03-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At ACADIA PHARMACEUTICALS INC.'s shareholder meeting held 2025-05-29, in the 2024-2025 proxy season, 344 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,969 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. ACADIA PHARMACEUTICALS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — To approve, on an advisory basis, the compensation of the Company's named executive officers… — the reporting funds cast 99.2% of the shares they voted in favour (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). That is the aggregate of those managers' own N-PX disclosures, not the company's certified result, and the funds are a subset of all shareholders.

ACADIA PHARMACEUTICALS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.